Final-Program-ATS-2023-AP.vp

40

SUNDAY • MAY 21

Target Audience Providers of lung health care, those who provide care to patients with COPD/emphysema, and basic and translational scientists with an interest in COPD/emphysema and gene x environment interactions Objectives At the conclusion of this session, the participant will be able to: • apply emerging data to identify cell types and lung compartments injured in COPD to more accurately discuss disease biology and likely disease trajectories with patients to improve care quality • understand existing gaps in the knowledge of pathobiology in COPD • identify emerging resources and data being applied to facilitate future therapeutic development Therapeutic discoveries have not kept pace with the significant, world-wide burden of disease associated with COPD/emphysema. No major class of drugs has introduced for COPD therapy in decades, suggesting the urgent need to delineate disease mechanisms that will facilitate drug discovery. Multiple recent publications have detailed at single-cell resolution the cellular transcriptional response to chronic smoke exposure and COPD/emphysema, particularly in the in the distal airways and alveoli. This session will explore approaches, including the integration of multi-omic datasets and the application of longitudinal cohorts and novel model systems that will extend understanding of disease mechanisms to facilitate therapeutic discovery. Chairing: A.A. Wilson, MD, Boston, MA A.X. Zhou, PhD, Boston, MA M.C. Basil, MD, PhD, Philadelphia, PA 9:00 RASCs, BASCs, or TASCs? ASCing What Cells in the Respiratory Bronchioles Contribute to COPD Pathogenesis M.C. Basil, MD, PhD, Philadelphia, PA 9:13 CAPitalizing on Single Cell RNA Sequencing to Identify Dysregulated Alveolar Endothelium in COPD M. Sauler, MD, New Haven, CT 9:26 Integrating GWAS Signals with Omics Datasets to Identify Causal Variants in COPD M.H. Cho, MPH, MD, Boston, MA 9:39 Application of Human iPSC Model Systems to Illuminate the Functional Contribution of COPD GWAS Genes to Cellular Phenotypes R. Werder, PhD, Melbourne, Australia 9:52 Novel Signaling Pathways as Potential Therapeutic Targets in COPD Pathogenesis E.R. Neptune, MD, ATSF, Baltimore, MD 10:04 Can Insights from the Pediatric Lung Teach Us About COPD? X. Sun, PhD, San Diego, CA

Occupational and environmental lung diseases are caused by the inhalation of chemical irritants, allergens or toxins in work or home environments. Most diseases are caused by repeated, long-term exposure, but even a one-time or indirect contact with a hazardous agent can result in lung diseases with lasting effects. Environmental exposures related to fossil fuel and heavy metals and occupational exposures related to silica and coal mining generate oxidative stress and inflammation in the lungs. Sustained oxidative stress causes DNA damage, epigenetic instability, mitochondrial dysfunction, and cell cycle arrest in key progenitor cells in the lung. Inhaled environmental exposures accelerate lung aging by injuring the lungs and damaging the cells responsible for wound healing. Novel exposure assessment methods, including functional imaging and -omics studies, together with mathematical models are needed to quantify environmental exposures. Interventions that minimize exposure to noxious antigens are critical to improve lung health, and novel research is required to expand our knowledge of therapies that may slow or prevent premature lung aging. Each presentation will leave 5 minutes for questions and answers. Chairing: I. Yang, PhD, ATSF, Aurora, CO

J. Woods, PhD, ATSF, Cincinnati, OH L. Alexander, MD, ATS, San Diego, CA

9:00

Quantifying Vaping-Related Pulmonary Illnesses I. Jaspers, PhD, Chapel Hill, NC Long-Term Exposure to Ambient Air Pollution and Change in Quantitatively Assessed Emphysema and Lung Function R. G. Barr, MD, DrPH, New York, NY Identifying Epigenetic Modifications to Allergens and Pollution C. Carlsten, MD, MPH, Vancouver, Canada

9:30

9:50

10:10

Visualizing Lung Destruction and Repair to Environmental Exposures T.L. Hackett, PhD, ATSF, Vancouver, Canada

10:25

Questions and Answers

BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

A6 BEYOND TRANSCRIPTOMICS: THE NEXT FRONTIER IN COPD/EMPHYSEMA Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Section on Genetics and Genomics 9:00 AM - 10:30 AM Walter E. Washington Convention Center Room 146 A-C (Street Level)

ATS 2023 • Washington, DC